Cargando…

Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation

Detalles Bibliográficos
Autores principales:	Mirea, L, Vasiliu, I Luca, Ungureanu, R, Balanescu, A, Grintescu, I
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3061754/ http://dx.doi.org/10.1186/cc9544

Ejemplares similares

Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis
por: de Pont, Anne CJM, et al.
Publicado: (2009)

Introduction: severe sepsis and drotrecogin alfa (activated)
por: Artigas, Antonio, et al.
Publicado: (2007)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
por: Beale, R, et al.
Publicado: (2007)

Increasing microcirculation after drotrecogin alfa (activated)
por: Donati, A, et al.
Publicado: (2007)

Retrospective observational outcomes for drotrecogin alfa (activated)
por: Cameron, C, et al.
Publicado: (2007)

Neuroaxial catheters following abdominal surgery and their impact on the use of Drotrecogin alfa (activated) in sepsis
por: Steel, A, et al.
Publicado: (2004)

Clinical trials in severe sepsis with drotrecogin alfa (activated)
por: Laterre, Pierre-François
Publicado: (2007)

Timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Choi, Goda, et al.
Publicado: (2006)

Use of national guidelines for the introduction of Drotrecogin alfa (activated)
por: Mackenzie, S, et al.
Publicado: (2004)

Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
por: Dhainaut, J, et al.
Publicado: (2008)

Drotrecogin alfa (activated) does not impair platelet receptor expression in vitro
por: Schuerholz, T, et al.
Publicado: (2004)

The safety profile of drotrecogin alfa (activated)
por: Fumagalli, Roberto, et al.
Publicado: (2007)

Drotrecogin alfa in sepsis: analysis of outcomes in a UK district general intensive care unit
por: Pathak, H, et al.
Publicado: (2004)

Drotrecogin alfa: start early, ensure response, stop early!
por: Jog, S, et al.
Publicado: (2008)

Drotrecogin alfa in patients with severe sepsis: experience from a tertiary care center in North India
por: Chawla, R, et al.
Publicado: (2007)

Testing of anti-activated protein C antibodies in four drotrecogin alfa (activated) severe sepsis studies
por: Yan, S, et al.
Publicado: (2008)

Is a combined i.v. and enteral glutamine regimen superior to a single i.v. glutamine regimen in severe thoracic trauma?
por: Pavelescu, D, et al.
Publicado: (2013)

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
por: Bernard, Gordon R, et al.
Publicado: (2003)

Drotrecogin alfa (activated): a single-centre experience of 110 patients
por: Fletcher, S, et al.
Publicado: (2010)

Multicentre audit of the use of drotrecogin alfa (activated) in UK critical care units
por: Rowan, K, et al.
Publicado: (2007)

A large, single-centre UK registry of drotrecogin alfa-activated use
por: Macchiavello, L, et al.
Publicado: (2007)

Eligibility for drotrecogin alfa therapy on the basis of APACHE II score and organ failure
por: Shulman, R, et al.
Publicado: (2005)

Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy
por: Camporota, Luigi, et al.
Publicado: (2008)

Impact of corticosteroid administration in septic shock on glycemic variability
por: Mirea, L, et al.
Publicado: (2014)

Continuous administration of corticosteroids in septic shock can reduce risk of hypernatremia
por: Mirea, L, et al.
Publicado: (2014)

Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
por: Friedrich, Jan O, et al.
Publicado: (2006)

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
por: Levy, Howard, et al.
Publicado: (2005)

Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis
por: Annane, Djillali, et al.
Publicado: (2018)

Three years experience with drotrecogin alfa (activated) protein C in severe sepsis and septic shock at Salmaniya Medical Complex, Bahrain
por: Mohamed, H, et al.
Publicado: (2007)

Practical aspects of treatment with drotrecogin alfa (activated)
por: Camporota, Luigi, et al.
Publicado: (2007)

Audit of adherence to National Institute of Clinical Excellence guidelines for the use of drotrecogin alfa (activated)
por: Vedantham, R, et al.
Publicado: (2007)

Global end-diastolic volume: a better indicator of cardiac preload in patients with septic shock
por: Mirea, L, et al.
Publicado: (2015)

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death
por: Gupta, Sanjay, et al.
Publicado: (2006)

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
por: Sadique, M Zia, et al.
Publicado: (2011)

Drotrecogin alfa (activated): down and not out, but not really in either
por: Friedrich, Jan O, et al.
Publicado: (2006)

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
por: Friedrich, Jan O, et al.
Publicado: (2006)

Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
por: Costa, Vania, et al.
Publicado: (2007)

Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
por: Spapen, Herbert, et al.
Publicado: (2010)

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
por: Martin, Greg, et al.
Publicado: (2009)

Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients
por: Launois, R, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_1ha7al6dcs4kslmhsbe21amfku